Aviado · Research
Longevity Daily
Saturday, November 7, 2026
Listen
Today's Brief
Today's stories probe the gap between mechanism and clinical proof. Our must-read asks whether we're entering a true era of Alzheimer's prevention — the science is now genuinely actionable for those who start early. The supplement world gets its most rigorous human data point in years, with NOVOS Core's placebo-controlled trial showing real vascular gains; Aviado's deep dive on L-citrulline explains the cleaner mechanism behind the effect. And a major Phase 3 trial delivered a sobering blow to pelacarsen, the promising Lp(a) drug that failed to prevent heart attacks after nearly five years.
10 stories5 peer-reviewed2 trials1 Aviado original
Cognitive Health & Neuroprotection
We May Be Entering a New Era of Alzheimer's Prevention — Here's What It Takes to Act Now
NBC News producer Susan Kroll discovered early Alzheimer's biomarkers on a screening test, then overhauled her lifestyle — and her story anchors a broader question the field is finally ready to answer. The latest evidence suggests we are approaching a preventive window, with sleep, exercise, diet, and early detection tools showing genuine promise for high-risk individuals who act before symptoms arrive. Experts caution that most drug trials have targeted the wrong stage of disease, but lifestyle changes pursued in midlife may move the needle in ways nothing else currently can. This is the most accessible, personally grounded overview of where Alzheimer's prevention science stands right now.
Read more →Rapamycin May Protect High-Risk Brains from Alzheimer's Years Before Symptoms Begin
People carrying the APOE4 gene face the highest genetic risk for Alzheimer's, and new research suggests rapamycin may specifically benefit them by improving brain blood flow — potentially years before cognitive symptoms emerge. The findings point to a possible preventive window in middle age, adding momentum to growing interest in rapamycin as a broad-spectrum longevity compound with neuroprotective properties. Human trials are still needed to confirm whether improved blood flow translates to actual risk reduction, but the APOE4-specific angle makes this one of the more targeted leads in Alzheimer's prevention research.
Read more →Estrogen Exposure Across the Lifespan Shields the Aging Female Brain from Vascular Damage
In a cohort of 352 cognitively normal 70-year-old women, greater lifetime estrogen exposure — measured by reproductive lifespan and oral contraceptive use — was linked to meaningfully better late-life brain health, particularly reduced vascular damage. The findings add to growing evidence that the timing and cumulative duration of estrogen exposure matters for brain aging, not just symptom management around menopause. This is observational data, so causation isn't established, but the sample size and specificity of the brain markers make it a credible signal worth discussing with your physician.
Read more →Supplements & Compounds
Longevity Supplement Improves Artery Function and Cuts Blood Pressure in 6-Month Placebo-Controlled Trial
A placebo-controlled RCT of NOVOS Core in 61 healthy adults found improvements across three vascular measures after six months — endothelial function, arterial stiffness, and systolic blood pressure — with endothelial benefits appearing as early as one hour after the first dose. The multi-ingredient formula targets several aging-related pathways simultaneously, making it difficult to isolate which component is driving the effect. Researcher Brad Stanfield flagged the surprisingly large effect sizes as a reason for cautious optimism, suggesting independent replication is now the critical next step.
Read more →Why L-Citrulline Outperforms Arginine for Blood Pressure — and How to Use It
Most people buying arginine supplements are wasting their money: the liver degrades the majority of it before it can boost nitric oxide production, the molecule responsible for relaxing blood vessels. L-citrulline takes a smarter metabolic route, slipping past the liver and converting to arginine in the kidneys — delivering more usable arginine from a smaller dose. Across multiple studies, 3–6 grams of L-citrulline daily consistently lowers systolic blood pressure by 4–9 mmHg within one to eight weeks, making it one of the cleaner supplement plays for vascular health with a clear, documented mechanism.
Read the full Aviado analysis →Lactoferrin Shows Anti-Aging Promise — But the Evidence Gap Is Too Wide to Ignore
Lactoferrin has plausible geroprotective mechanisms, but as Fight Aging! lays out clearly, 'plausible' is exactly where the evidence stops for most longevity supplements. The uncomfortable economics: lengthy clinical trials rarely get funded for cheap, unpatentable compounds, so uncertainty persists indefinitely — and that's precisely the gap the supplement industry fills with marketing. If you're taking lactoferrin, you may be making a reasonable bet, but it's still a bet rather than a proven strategy.
Read more →Research & Papers
Chronic Rapamycin Use Shows No Survival Advantage in Long-Term Human Study
Rapamycin reliably extends lifespan in yeast, worms, flies, and mice — by up to 24% in fruit flies — but a long-term observational study of kidney transplant recipients found no detectable survival advantage from chronic rapamycin use in humans. Transplant patients represent a medically complex, immunosuppressed population, so results may not generalize to healthy adults taking low-dose rapamycin for longevity purposes. Still, the finding is a useful anchor: extrapolating model-organism results to humans remains one of aging biology's hardest unsolved problems, and the burden of proof for human benefit is high.
Read more →Metformin Cuts Long COVID and Death Risk by 53% — If Prescribed Within 6 Days
A Journal of Medical Virology study found that COVID-19 patients prescribed metformin within six days of infection were 53% less likely to develop long COVID or die compared to those who weren't prescribed the drug. The finding adds to growing evidence that metformin's anti-inflammatory and metabolic effects extend well beyond blood sugar management, reinforcing its profile as a broad-spectrum geroprotective compound. The study is observational — sicker patients may have been less likely to receive metformin — so a randomized trial is needed to confirm causation, but the effect size is striking enough to warrant close attention.
Read more →Lifestyle & Nutrition
Blueberries Have the Strongest Vascular Evidence of Any Fruit, Harvard Researchers Confirm
Harvard researchers and biomedical scientist Rhonda Patrick both point to blueberries as one of the best-evidenced foods for brain and heart health, with Patrick describing the vascular data as 'the strongest' for any single fruit. The benefits are driven largely by anthocyanins, which improve blood vessel function and reduce chronic inflammation — mechanisms directly relevant to both cardiovascular and cognitive aging. This isn't breaking news, but it is a timely reminder that one of the most accessible, affordable interventions in longevity nutrition has real biological backing.
Read more →Industry & Policy
Phase 3 Blow: Lp(a)-Lowering Drug Pelacarsen Fails to Prevent Heart Attacks After Nearly 5 Years
The Phase 3 HORIZON trial — enrolling patients with elevated lipoprotein(a) and existing cardiovascular disease — found that pelacarsen significantly reduced Lp(a) levels but did not translate to fewer major cardiovascular events over nearly five years of follow-up. The result is a significant setback for Lp(a) as a drug target, echoing the hard lesson that lowering a biomarker doesn't always mean lowering risk. Other Lp(a)-lowering approaches, including CRISPR-based gene editing and oral agents like muvalaplin, remain in development — but this trial raises the stakes for how the field defines success.
Read more →